The acquisition is expected to strengthen the company’s position in advanced in- vitro diagnostic (IVD) market in China.
The company expects the acquisition to be accretive immediately from the current quarter ending March 31, 2008, resulting in increases in both revenues and adjusted non-GAAP net income.